Teva announced the company has completed the purchase of three buildings on Brandywine Parkway in West Chester, Pa., which, together with three other buildings Teva owns in the same corporate park, establishes a North America Research & Development (R&D) campus. Focused primarily on biologics, the R&D campus further augments the company’s significant U.S. presence.
“With our late-stage biologics R&D development teams co-located on a single campus, the company has created a one-stop shop for biologics development and clinical manufacturing,” said Mehran Yazdanian, Senior Director, Specialty R&D Scientific Strategy & Operations, Global R&D and Site Head. “From cell bank to syringe, our West Chester R&D campus is home to many of the North American-based R&D teams and processes that will bring more biologics treatment options to patients, and support Teva’s global mission to improve lives.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Teva purchased 400, 500 and 600 Brandywine Parkway, which the company had been leasing since 2007 and, along with 100, 200 and 300 Brandywine Parkway, now owns approximately 314,000 square feet in West Chester dedicated to feeding Teva’s future pipeline and portfolio.
Teva’s West Chester R&D campus houses clinical development and manufacturing processes for highly complex biologic medicines developed by Teva. The campus also includes laboratories where advanced preclinical and clinical testing is conducted to ensure the safety and effectiveness of new drugs. Approximately 650 employees will be based at Teva in West Chester by the end of 2019, including teams involved in combination product and device R&D, regulatory affairs, medical affairs, and support functions.
Teva employs approximately 7,000 employees in multiple locations in the US in manufacturing, commercial, R&D and administrative functions.